{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:13:00Z","timestamp":1762899180134},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T00:00:00Z","timestamp":1442880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Abiraterone Acetate (AA) and Enzalutamide (Enz) are effective hormonal treatments in mCRPC patients. Retrospective studies suggested clinical cross\u2010resistance between Enz and AA. However, 12.8\u201339.1% of patients previously treated with docetaxel (Doc) and AA do respond to Enz. These responders have not been characterized.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>102 Enz treated mCRPC patients after AA and Doc treatment were included in this study. Differences in patient characteristics and previous treatment outcomes between PSA responders and non\u2010responders on Enz were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Median Progression\u2010Free Survival was 12.2 weeks (95%CI 11.7\u201314.3) and Overall Survival 43.5 weeks (95%CI 37.4\u201361.2). There were 26 (25%) Enz\u2010responders and 76 (75%) non\u2010responders. Significant higher percentages of Gleason scores \u22658 and PSA doubling times (PSA\u2010DT) &lt;3 months were found in Enz responders than in non\u2010responders. The interval between end of AA and start of Enz treatment (IAE) for responders was 24.6 weeks (IQR 4.0\u201048.1) and 8.9 weeks for non\u2010responders (IQR 3.7\u201325.9) (P\u2009=\u20090.08). In an IAE &lt;40 days subgroup (34 patients), Enz responses were related to AA non\u2010responsiveness, while univariate and logistic regression analysis of baseline criteria of a subgroup of patients with an IAE\u226540 (68 patients) revealed significant differences in baseline PSA levels, PSA\u2010DT &lt;3 months, Gleason scores \u22658 and IAE's between Enz responders and non\u2010responders.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>PSA response to Enz after previous AA and Doc treatment was associated with a longer IAE, a higher Gleason score and a PSA\u2010DT &lt;3 months. Identification of these patients might be of value for sequencing of treatment options. <jats:italic>Prostate 76:32\u201340, 2016<\/jats:italic>. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.23094","type":"journal-article","created":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T07:53:02Z","timestamp":1442908382000},"page":"32-40","source":"Crossref","is-referenced-by-count":12,"title":["Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration\u2010resistant prostate cancer patients; a possible time relation"],"prefix":"10.1002","volume":"76","author":[{"given":"Sushil K.","family":"Badrising","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Netherlands Cancer Institute Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"van der Noort","sequence":"additional","affiliation":[{"name":"Department of Biometrics Netherlands Cancer Institute Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfons J.M.","family":"van den Eertwegh","sequence":"additional","affiliation":[{"name":"Department of Oncology VU University Medical Center Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Hamberg","sequence":"additional","affiliation":[{"name":"Department of Oncology &amp; Prostate Cancer Center Sint Franciscus Gasthuis Rotterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[{"name":"Department of Urology Radboud University Nijmegen Medical Centre Nijmegen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik P.","family":"van den Berg","sequence":"additional","affiliation":[{"name":"Department of Oncology Tergooi Ziekenhuizen Blaricum the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maartje","family":"Los","sequence":"additional","affiliation":[{"name":"Department of Oncology Sint Antonius Hospital Nieuwegein the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen J.B.","family":"Aarts","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Maastricht University Medical Centre Maastricht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules L.L.M.","family":"Coenen","sequence":"additional","affiliation":[{"name":"Department of Oncology Isala Klinieken Zwolle the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Leiden University Medical Center the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igle J.","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Urology University of Groningen Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emile D.","family":"Kerver","sequence":"additional","affiliation":[{"name":"Department of Oncology OLVG Hospital Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzan","family":"Vrijaldenhoven","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Medisch Centrum Alkmaar Alkmaar the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"van Voorthuizen","sequence":"additional","affiliation":[{"name":"Department of Oncology Rijnstate Hospital Arnhem the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Warmerdam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Oncology Atrium\u2010Orbis Medical Center Heerlen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Haanen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Netherlands Cancer Institute Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andries M.","family":"Bergman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Netherlands Cancer Institute Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the Dutch Uro\u2010Oncology Studygroup (DUOS)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,22]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/35094009"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601879"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28518"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.08.020"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.12.017"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.042"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/21681805.2013.860189"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.028"},{"key":"e_1_2_5_14_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eururo.2014.10.014","article-title":"Clinical outcomes of castration\u2010resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second\u2010line treatment: Results of an Italian multicentre study","volume":"68","author":"Caffo O","year":"2014","journal-title":"Eur Urol"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_5_17_1","unstructured":"The R Core Team. R: A language and environment for statistical computing. R foundation for Statistical Computing [Internet]. R Foundation for Statistical Computing Vienna Austria;2013. Available from:http:\/\/www.r\u2010project.org."},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.06.045"},{"key":"e_1_2_5_19_1","unstructured":"EMA: Xtandi Summary of Product Characteristics.2014; Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002639\/WC500144996.pdf."},{"key":"e_1_2_5_20_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1464-410X.2011.10422.x","article-title":"The natural history of metastatic progression in men with prostate\u2010specific antigen recurrence after radical prostatectomy: long\u2010term follow\u2010up","volume":"109","author":"Antonarakis ES","journal-title":"BJU Int"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-14-31"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.04.005"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.01.015"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-0254-1_7"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.04.008"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23094","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.23094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:34:52Z","timestamp":1696527292000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.23094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,22]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1002\/pros.23094"],"URL":"https:\/\/doi.org\/10.1002\/pros.23094","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"type":"print","value":"0270-4137"},{"type":"electronic","value":"1097-0045"}],"subject":[],"published":{"date-parts":[[2015,9,22]]}}}